Arrowhead Pharmaceuticals, Inc. (ARWR)

$27.23

+0.22

(+0.81%)▲

Market is closed - opens 7 PM, 22 Sep 2023

Insights on Arrowhead Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 146.26M → 15.82M (in $), with an average decrease of 89.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 48.67M → -102.94M (in $), with an average decrease of 311.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 283.9% return, outperforming this stock by 300.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 452.1% return, outperforming this stock by 487.3%

Performance

  • $26.52
    $27.62
    $27.23
    downward going graph

    2.61%

    Downside

    Day's Volatility :3.97%

    Upside

    1.39%

    downward going graph
  • $23.09
    $42.48
    $27.23
    downward going graph

    15.2%

    Downside

    52 Weeks Volatility :45.65%

    Upside

    35.9%

    downward going graph

Returns

PeriodArrowhead Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-23.98%
0.0%
0.0%
6 Months
9.8%
3.0%
-0.5%
1 Year
-16.84%
7.2%
0.4%
3 Years
-35.24%
27.5%
19.1%

Highlights

Market Capitalization
2.9B
Book Value
$3.41
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.66
PEG Ratio
-1.32
Wall Street Target Price
56.71
Profit Margin
-70.69%
Operating Margin TTM
-70.45%
Return On Assets TTM
-14.58%
Return On Equity TTM
-43.03%
Revenue TTM
256.2M
Revenue Per Share TTM
2.41
Quarterly Revenue Growth YOY
-51.2%
Gross Profit TTM
243.2M
EBITDA
-169.2M
Diluted Eps TTM
-1.66
Quarterly Earnings Growth YOY
0.1
EPS Estimate Current Year
-1.53
EPS Estimate Next Year
-2.77
EPS Estimate Current Quarter
-0.65
EPS Estimate Next Quarter
-0.77

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Arrowhead Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
15
14
Hold
4
4
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 108.26%

Current $27.23
Target $56.71

Company Financials

FY17Y/Y Change
Revenue
31.4M
↑ 19736.49%
Net Income
-34.4M
↓ 57.93%
Net Profit Margin
-109.46%
↑ 51505.18%
FY18Y/Y Change
Revenue
16.1M
↓ 48.6%
Net Income
-54.5M
↑ 58.38%
Net Profit Margin
-337.32%
↓ 227.86%
FY19Y/Y Change
Revenue
168.8M
↑ 945.67%
Net Income
68.0M
↓ 224.84%
Net Profit Margin
40.27%
↑ 377.59%
FY20Y/Y Change
Revenue
88.0M
↓ 47.87%
Net Income
-84.6M
↓ 224.39%
Net Profit Margin
-96.09%
↓ 136.36%
FY21Y/Y Change
Revenue
138.3M
↑ 57.16%
Net Income
-140.8M
↑ 66.58%
Net Profit Margin
-101.85%
↓ 5.76%
FY22Y/Y Change
Revenue
243.2M
↑ 75.89%
Net Income
-176.1M
↑ 25.0%
Net Profit Margin
-72.39%
↑ 29.46%
Q1 FY22Q/Q Change
Revenue
151.8M
↑ 453.25%
Net Income
44.4M
↓ 170.57%
Net Profit Margin
29.23%
↑ 258.36%
Q2 FY22Q/Q Change
Revenue
32.4M
↓ 78.65%
Net Income
-72.0M
↓ 262.39%
Net Profit Margin
-222.28%
↓ 251.51%
Q3 FY22Q/Q Change
Revenue
31.6M
↓ 2.58%
Net Income
-85.5M
↑ 18.69%
Net Profit Margin
-270.82%
↓ 48.54%
Q4 FY22Q/Q Change
Revenue
62.5M
↑ 98.09%
Net Income
-41.3M
↓ 51.67%
Net Profit Margin
-66.07%
↑ 204.75%
Q1 FY23Q/Q Change
Revenue
146.3M
↑ 133.86%
Net Income
48.7M
↓ 217.79%
Net Profit Margin
33.28%
↑ 99.35%
Q2 FY23Q/Q Change
Revenue
15.8M
↓ 89.18%
Net Income
-102.9M
↓ 311.5%
Net Profit Margin
-650.53%
↓ 683.81%
FY17Y/Y Change
Total Assets
104.0M
↓ 18.84%
Total Liabilities
23.2M
↓ 30.16%
FY18Y/Y Change
Total Assets
111.6M
↑ 7.29%
Total Liabilities
16.4M
↓ 29.31%
FY19Y/Y Change
Total Assets
349.8M
↑ 213.45%
Total Liabilities
105.8M
↑ 546.4%
FY20Y/Y Change
Total Assets
522.5M
↑ 49.35%
Total Liabilities
60.7M
↓ 42.61%
FY21Y/Y Change
Total Assets
710.1M
↑ 35.91%
Total Liabilities
301.3M
↑ 396.22%
FY22Y/Y Change
Total Assets
691.9M
↓ 2.56%
Total Liabilities
273.6M
↓ 9.2%
Q1 FY22Q/Q Change
Total Assets
703.6M
↑ 10.19%
Total Liabilities
251.3M
↓ 5.52%
Q2 FY22Q/Q Change
Total Assets
751.8M
↑ 6.85%
Total Liabilities
277.6M
↑ 10.46%
Q3 FY22Q/Q Change
Total Assets
691.9M
↓ 7.96%
Total Liabilities
273.6M
↓ 1.44%
Q4 FY22Q/Q Change
Total Assets
891.5M
↑ 28.84%
Total Liabilities
495.1M
↑ 80.96%
Q1 FY23Q/Q Change
Total Assets
891.3M
↓ 0.02%
Total Liabilities
426.2M
↓ 13.92%
Q2 FY23Q/Q Change
Total Assets
795.9M
↓ 10.71%
Total Liabilities
413.9M
↓ 2.89%
FY17Y/Y Change
Operating Cash Flow
-23.9M
↓ 62.84%
Investing Cash Flow
-48.6M
↓ 461.73%
Financing Cash Flow
12.1M
↓ 78.13%
FY18Y/Y Change
Operating Cash Flow
-47.2M
↑ 97.27%
Investing Cash Flow
-7.4M
↓ 84.72%
Financing Cash Flow
60.0M
↑ 397.32%
FY19Y/Y Change
Operating Cash Flow
173.0M
↓ 466.42%
Investing Cash Flow
-47.7M
↑ 542.18%
Financing Cash Flow
66.4M
↑ 10.72%
FY20Y/Y Change
Operating Cash Flow
-95.4M
↓ 155.13%
Investing Cash Flow
-240.8M
↑ 404.29%
Financing Cash Flow
257.9M
↑ 288.58%
FY21Y/Y Change
Operating Cash Flow
171.2M
↓ 279.5%
Investing Cash Flow
-141.7M
↓ 41.16%
Financing Cash Flow
11.3M
↓ 95.62%
FY22Y/Y Change
Operating Cash Flow
-136.1M
↓ 179.5%
Investing Cash Flow
-5.4M
↓ 96.18%
Financing Cash Flow
65.2M
↑ 476.61%
Q1 FY22Q/Q Change
Operating Cash Flow
62.7M
↓ 202.25%
Investing Cash Flow
-69.8M
↑ 108.94%
Financing Cash Flow
1.8M
↓ 2.07%
Q2 FY22Q/Q Change
Operating Cash Flow
-68.8M
↓ 209.75%
Investing Cash Flow
61.3M
↓ 187.85%
Financing Cash Flow
60.6M
↑ 3182.77%
Q3 FY22Q/Q Change
Operating Cash Flow
-68.7M
↓ 0.26%
Investing Cash Flow
36.4M
↓ 40.53%
Financing Cash Flow
855.0K
↓ 98.59%
Q4 FY22Q/Q Change
Operating Cash Flow
-75.5M
↑ 9.97%
Investing Cash Flow
-80.7M
↓ 321.41%
Financing Cash Flow
250.6M
↑ 29207.13%
Q1 FY23Q/Q Change
Operating Cash Flow
-31.7M
↓ 58.06%
Investing Cash Flow
-36.1M
↓ 55.31%
Financing Cash Flow
520.0K
↓ 99.79%

Technicals Summary

Sell

Neutral

Buy

Arrowhead Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
-5.82%
9.8%
-16.84%
-35.24%
52.0%
Moderna, Inc.
Moderna, Inc.
-6.8%
-31.93%
-17.68%
49.48%
456.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.51%
9.46%
21.47%
49.65%
113.08%
Novo Nordisk A/s
Novo Nordisk A/s
2.45%
158.58%
283.85%
452.05%
699.12%
Seagen, Inc.
Seagen, Inc.
7.08%
3.54%
46.23%
15.75%
166.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
16.4%
25.65%
33.45%
95.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
NA
NA
-1.32
-1.53
-0.43
-0.15
0.0
3.41
Moderna, Inc.
Moderna, Inc.
39.67
39.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.65
21.65
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
44.47
44.47
2.03
3.32
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.47
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.73
26.73
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Buy
$2.9B
52.0%
NA
-70.69%
Moderna, Inc.
Moderna, Inc.
Buy
$39.4B
456.61%
39.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.3B
113.08%
21.65
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$423.8B
699.12%
44.47
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.9B
166.19%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.9B
95.64%
26.73
35.4%

Institutional Holdings

  • BlackRock Inc

    11.95%

  • Vanguard Group Inc

    10.24%

  • State Street Corporation

    5.14%

  • JPMorgan Chase & Co

    2.69%

  • FMR Inc

    2.54%

  • Amvescap Plc.

    2.08%

Corporate Announcements

  • Arrowhead Pharmaceuticals, Inc. Earnings

    Arrowhead Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

Organization
Arrowhead Pharmaceuticals, Inc.
Employees
397
CEO
Dr. Christopher R. Anzalone Ph.D.
Industry
Health Technology

Discover More

FAQs